Annexon, Inc. (ANNX) 10-Year Financial Performance & Capital Metrics

ANNX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Show more

Revenue $0
EBITDA -$151M -6.4%
Net Income -$138M -3.0%
EPS (Diluted) -1.01 +42.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -50.84% +8.8%
ROIC -70.17% +41.1%
Debt/Equity 0.10 -21.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 81.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-76.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-34.29%

ROCE

10Y Avg-100.22%

5Y Avg-46.98%

3Y Avg-53.18%

Latest-51.42%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	271K	488K	0	0	0	0	0	3.45M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-271K	-488K	0	0	0	0	0	-3.45M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.8%	1%	-	-	-	-	-
Operating Expenses+	20.21M	19.15M	32.52M	63.47M	130.71M	145.6M	143.72M	150.62M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.35M	3.62M	7.99M	14.2M	30.65M	30.95M	28.02M	34.63M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	17.85M	15.53M	24.52M	49.27M	100.07M	112.5M	113.76M	119.45M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	844K	0	0	0	2.15M	1.95M	-3.45M
Operating Income+	-20.48M	-19.15M	-32.52M	-63.47M	-130.71M	-145.6M	-143.72M	-154.07M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.06%	-0.7%	-0.95%	-1.06%	-0.11%	0.01%	-0.07%
EBITDA+	-20.21M	-18.66M	-32.02M	-62.8M	-128.57M	-143.45M	-141.57M	-150.62M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.08%	-0.72%	-0.96%	-1.05%	-0.12%	0.01%	-0.06%
D&A (Non-Cash Add-back)	271K	488K	493K	667K	2.14M	2.15M	2.15M	3.45M
EBIT	-20.48M	-19.15M	-32.52M	-63.47M	-130.71M	-145.6M	-143.72M	-138.2M
Net Interest Income+	0	0	0	0	0	3.65M	9.49M	0
Interest Income	370K	0	0	0	0	3.65M	9.49M	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	1.77M	844K	-4.66M	57K	390K	3.65M	9.49M	15.87M
Pretax Income+	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	1K	1K	4K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.02%	-1.03%	-0.71%	-1.06%	-0.09%	0.05%	-0.03%
Net Income (Continuing)	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.49	-1.60	-0.97	-3.70	-3.34	-2.60	-1.77	-1.01
EPS Growth %	-	-2.27%	0.39%	-2.81%	0.1%	0.22%	0.32%	0.43%
EPS (Basic)	-0.49	-1.60	-0.97	-3.70	-3.34	-2.60	-1.77	-1.01
Diluted Shares Outstanding	38.22M	11.45M	38.22M	16.96M	38.32M	54.67M	75.67M	137.4M
Basic Shares Outstanding	38.22M	11.45M	38.22M	16.96M	38.32M	54.67M	75.67M	137.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.89M	45.71M	45.41M	354.01M	247.69M	248.1M	263.86M	316.46M
Cash & Short-Term Investments	2.97M	44.17M	43.93M	351.21M	242.72M	242.66M	259.72M	312.02M
Cash Only	2.97M	44.17M	43.93M	268.56M	74.84M	140.02M	225.11M	49.5M
Short-Term Investments	0	0	0	82.64M	167.87M	102.64M	34.61M	262.52M
Accounts Receivable	582K	225K	79K	3K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	463K	203K	63K	1.1M
Total Non-Current Assets+	2.93M	2.44M	4.49M	1.94M	39.35M	37M	33.81M	33.61M
Property, Plant & Equipment	2.82M	2.35M	2.14M	1.94M	38.18M	35.97M	32.78M	29.34M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	1.03M	0	0
Other Non-Current Assets	112K	98K	2.35M	0	1.17M	0	1.03M	4.27M
Total Assets+	7.82M	48.15M	49.9M	355.95M	287.04M	285.1M	297.67M	350.07M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	5.16%	0.04%	6.13%	-0.19%	-0.01%	0.04%	0.18%
Total Current Liabilities+	2.92M	3.33M	4.93M	10.62M	21.74M	22.36M	17.93M	30.51M
Accounts Payable	1.52M	1.27M	2.37M	3.73M	11.15M	7.42M	5.49M	10.43M
Days Payables Outstanding	2.05K	950.65	-	-	-	-	-	1.1K
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	971K	342K	366K	2.93M	2.06M	180K	5.65M	5.97M
Current Ratio	1.68x	13.74x	9.21x	33.33x	11.39x	11.10x	14.72x	10.37x
Quick Ratio	1.68x	13.74x	9.21x	33.33x	11.39x	11.10x	14.72x	10.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	51.12M	6.94M	1.44M	1.05M	33.39M	31.54M	29.19M	26.45M
Long-Term Debt	0	107.22M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	33.39M	31.54M	29.19M	26.45M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	51.12M	-100.28M	1.44M	1.05M	0	0	0	0
Total Liabilities	54.03M	10.27M	6.37M	11.67M	55.13M	53.9M	47.12M	56.97M
Total Debt+	48.97M	107.22M	0	0	34.59M	32.86M	31.36M	28.97M
Net Debt	46.01M	63.05M	-43.93M	-268.56M	-40.25M	-107.16M	-193.75M	-20.53M
Debt / Equity	-	2.83x	-	-	0.15x	0.14x	0.13x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-46.21M	37.88M	43.53M	344.28M	231.91M	231.19M	250.56M	293.11M
Equity Growth %	-	1.82%	0.15%	6.91%	-0.33%	-0%	0.08%	0.17%
Book Value per Share	-1.21	3.31	1.14	20.30	6.05	4.23	3.31	2.13
Total Shareholders' Equity	-46.21M	37.88M	43.53M	344.28M	231.91M	231.19M	250.56M	293.11M
Common Stock	3K	4K	4K	38K	39K	48K	78K	109K
Retained Earnings	-47.09M	-65.4M	-102.58M	-165.99M	-296.31M	-438.26M	-572.5M	-710.7M
Treasury Stock	-905K	0	0	0	0	0	0	0
Accumulated OCI	-26K	-66K	-80K	-77K	-180K	-372K	-52K	10K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.26M	-17.19M	-28.36M	-53.09M	-106.11M	-116.31M	-121.14M	-118.01M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.11%	-0.65%	-0.87%	-1%	-0.1%	-0.04%	0.03%
Net Income	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Depreciation & Amortization	271K	488K	493K	667K	3.41M	2.11M	2.15M	2.15M
Stock-Based Compensation	401K	408K	2.04M	4.89M	0	18.52M	18.18M	19.43M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	799K	-260K	5.67M	53K	17.52M	1.28M	-1.43M	-7.75M
Working Capital Changes	-1.22M	478K	625K	4.72M	3.28M	3.74M	-5.8M	6.36M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	144K	-253K	931K	1.51M	3.86M	-287K	-2.08M	4.94M
Cash from Investing+	-567K	-17K	-267K	-83.16M	-88.24M	58.44M	70.7M	-218.8M
Capital Expenditures	-567K	-17K	-267K	-464K	-1.65M	-6.53M	-193K	-15K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-82.7K	0	64.97K	0	0
Cash from Financing+	42K	58.46M	28.39M	360.88M	1.79M	122.91M	135.52M	161.21M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-6.22M	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	42K	121K	-1.6M	3.27M	0	-7.57M	14K	-665K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.83M	-17.21M	-28.63M	-53.55M	-107.76M	-122.83M	-121.33M	-118.02M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.13%	-0.66%	-0.87%	-1.01%	-0.14%	0.01%	0.03%
FCF per Share	-0.52	-1.50	-0.75	-3.16	-2.81	-2.25	-1.60	-0.86
FCF Conversion (FCF/Net Income)	1.03x	0.94x	0.76x	0.84x	0.81x	0.82x	0.90x	0.85x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	1K	2K	0	0	0	0	4.89M

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-48.32%	-91.35%	-32.7%	-45.24%	-61.3%	-55.73%	-50.84%
Return on Invested Capital (ROIC)	-	-28.51%	-48.52%	-126.41%	-73.33%	-69.18%	-119.22%	-70.17%
Debt / Equity	-	2.83x	-	-	0.15x	0.14x	0.13x	0.10x
FCF Conversion	1.03x	0.94x	0.76x	0.84x	0.81x	0.82x	0.90x	0.85x

Frequently Asked Questions

Growth & Financials

Annexon, Inc. (ANNX) grew revenue by 0.0% over the past year. Growth has been modest.

Annexon, Inc. (ANNX) reported a net loss of $207.0M for fiscal year 2024.

Dividend & Returns

Annexon, Inc. (ANNX) has a return on equity (ROE) of -50.8%. Negative ROE indicates the company is unprofitable.

Annexon, Inc. (ANNX) had negative free cash flow of $176.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Annexon, Inc. (ANNX) 10-Year Financial Performance & Capital Metrics

ANNX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$151M -6.4%
Net Income -$138M -3.0%
EPS (Diluted) -1.01 +42.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -50.84% +8.8%
ROIC -70.17% +41.1%
Debt/Equity 0.10 -21.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 96 (top 4%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 81.6% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-76.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-34.29%

ROCE

10Y Avg-100.22%

5Y Avg-46.98%

3Y Avg-53.18%

Latest-51.42%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	271K	488K	0	0	0	0	0	3.45M
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	-271K	-488K	0	0	0	0	0	-3.45M
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.8%	1%	-	-	-	-	-
Operating Expenses+	20.21M	19.15M	32.52M	63.47M	130.71M	145.6M	143.72M	150.62M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	2.35M	3.62M	7.99M	14.2M	30.65M	30.95M	28.02M	34.63M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	17.85M	15.53M	24.52M	49.27M	100.07M	112.5M	113.76M	119.45M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	844K	0	0	0	2.15M	1.95M	-3.45M
Operating Income+	-20.48M	-19.15M	-32.52M	-63.47M	-130.71M	-145.6M	-143.72M	-154.07M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	0.06%	-0.7%	-0.95%	-1.06%	-0.11%	0.01%	-0.07%
EBITDA+	-20.21M	-18.66M	-32.02M	-62.8M	-128.57M	-143.45M	-141.57M	-150.62M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	0.08%	-0.72%	-0.96%	-1.05%	-0.12%	0.01%	-0.06%
D&A (Non-Cash Add-back)	271K	488K	493K	667K	2.14M	2.15M	2.15M	3.45M
EBIT	-20.48M	-19.15M	-32.52M	-63.47M	-130.71M	-145.6M	-143.72M	-138.2M
Net Interest Income+	0	0	0	0	0	3.65M	9.49M	0
Interest Income	370K	0	0	0	0	3.65M	9.49M	0
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	1.77M	844K	-4.66M	57K	390K	3.65M	9.49M	15.87M
Pretax Income+	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	1K	1K	4K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	0.02%	-1.03%	-0.71%	-1.06%	-0.09%	0.05%	-0.03%
Net Income (Continuing)	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.49	-1.60	-0.97	-3.70	-3.34	-2.60	-1.77	-1.01
EPS Growth %	-	-2.27%	0.39%	-2.81%	0.1%	0.22%	0.32%	0.43%
EPS (Basic)	-0.49	-1.60	-0.97	-3.70	-3.34	-2.60	-1.77	-1.01
Diluted Shares Outstanding	38.22M	11.45M	38.22M	16.96M	38.32M	54.67M	75.67M	137.4M
Basic Shares Outstanding	38.22M	11.45M	38.22M	16.96M	38.32M	54.67M	75.67M	137.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.89M	45.71M	45.41M	354.01M	247.69M	248.1M	263.86M	316.46M
Cash & Short-Term Investments	2.97M	44.17M	43.93M	351.21M	242.72M	242.66M	259.72M	312.02M
Cash Only	2.97M	44.17M	43.93M	268.56M	74.84M	140.02M	225.11M	49.5M
Short-Term Investments	0	0	0	82.64M	167.87M	102.64M	34.61M	262.52M
Accounts Receivable	582K	225K	79K	3K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	463K	203K	63K	1.1M
Total Non-Current Assets+	2.93M	2.44M	4.49M	1.94M	39.35M	37M	33.81M	33.61M
Property, Plant & Equipment	2.82M	2.35M	2.14M	1.94M	38.18M	35.97M	32.78M	29.34M
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	1.03M	0	0
Other Non-Current Assets	112K	98K	2.35M	0	1.17M	0	1.03M	4.27M
Total Assets+	7.82M	48.15M	49.9M	355.95M	287.04M	285.1M	297.67M	350.07M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	5.16%	0.04%	6.13%	-0.19%	-0.01%	0.04%	0.18%
Total Current Liabilities+	2.92M	3.33M	4.93M	10.62M	21.74M	22.36M	17.93M	30.51M
Accounts Payable	1.52M	1.27M	2.37M	3.73M	11.15M	7.42M	5.49M	10.43M
Days Payables Outstanding	2.05K	950.65	-	-	-	-	-	1.1K
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	971K	342K	366K	2.93M	2.06M	180K	5.65M	5.97M
Current Ratio	1.68x	13.74x	9.21x	33.33x	11.39x	11.10x	14.72x	10.37x
Quick Ratio	1.68x	13.74x	9.21x	33.33x	11.39x	11.10x	14.72x	10.37x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	51.12M	6.94M	1.44M	1.05M	33.39M	31.54M	29.19M	26.45M
Long-Term Debt	0	107.22M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	33.39M	31.54M	29.19M	26.45M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	51.12M	-100.28M	1.44M	1.05M	0	0	0	0
Total Liabilities	54.03M	10.27M	6.37M	11.67M	55.13M	53.9M	47.12M	56.97M
Total Debt+	48.97M	107.22M	0	0	34.59M	32.86M	31.36M	28.97M
Net Debt	46.01M	63.05M	-43.93M	-268.56M	-40.25M	-107.16M	-193.75M	-20.53M
Debt / Equity	-	2.83x	-	-	0.15x	0.14x	0.13x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-46.21M	37.88M	43.53M	344.28M	231.91M	231.19M	250.56M	293.11M
Equity Growth %	-	1.82%	0.15%	6.91%	-0.33%	-0%	0.08%	0.17%
Book Value per Share	-1.21	3.31	1.14	20.30	6.05	4.23	3.31	2.13
Total Shareholders' Equity	-46.21M	37.88M	43.53M	344.28M	231.91M	231.19M	250.56M	293.11M
Common Stock	3K	4K	4K	38K	39K	48K	78K	109K
Retained Earnings	-47.09M	-65.4M	-102.58M	-165.99M	-296.31M	-438.26M	-572.5M	-710.7M
Treasury Stock	-905K	0	0	0	0	0	0	0
Accumulated OCI	-26K	-66K	-80K	-77K	-180K	-372K	-52K	10K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.26M	-17.19M	-28.36M	-53.09M	-106.11M	-116.31M	-121.14M	-118.01M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	0.11%	-0.65%	-0.87%	-1%	-0.1%	-0.04%	0.03%
Net Income	-18.71M	-18.3M	-37.18M	-63.41M	-130.32M	-141.95M	-134.24M	-138.2M
Depreciation & Amortization	271K	488K	493K	667K	3.41M	2.11M	2.15M	2.15M
Stock-Based Compensation	401K	408K	2.04M	4.89M	0	18.52M	18.18M	19.43M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	799K	-260K	5.67M	53K	17.52M	1.28M	-1.43M	-7.75M
Working Capital Changes	-1.22M	478K	625K	4.72M	3.28M	3.74M	-5.8M	6.36M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	144K	-253K	931K	1.51M	3.86M	-287K	-2.08M	4.94M
Cash from Investing+	-567K	-17K	-267K	-83.16M	-88.24M	58.44M	70.7M	-218.8M
Capital Expenditures	-567K	-17K	-267K	-464K	-1.65M	-6.53M	-193K	-15K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-82.7K	0	64.97K	0	0
Cash from Financing+	42K	58.46M	28.39M	360.88M	1.79M	122.91M	135.52M	161.21M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	-6.22M	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	42K	121K	-1.6M	3.27M	0	-7.57M	14K	-665K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.83M	-17.21M	-28.63M	-53.55M	-107.76M	-122.83M	-121.33M	-118.02M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	0.13%	-0.66%	-0.87%	-1.01%	-0.14%	0.01%	0.03%
FCF per Share	-0.52	-1.50	-0.75	-3.16	-2.81	-2.25	-1.60	-0.86
FCF Conversion (FCF/Net Income)	1.03x	0.94x	0.76x	0.84x	0.81x	0.82x	0.90x	0.85x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	1K	2K	0	0	0	0	4.89M

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-48.32%	-91.35%	-32.7%	-45.24%	-61.3%	-55.73%	-50.84%
Return on Invested Capital (ROIC)	-	-28.51%	-48.52%	-126.41%	-73.33%	-69.18%	-119.22%	-70.17%
Debt / Equity	-	2.83x	-	-	0.15x	0.14x	0.13x	0.10x
FCF Conversion	1.03x	0.94x	0.76x	0.84x	0.81x	0.82x	0.90x	0.85x

Frequently Asked Questions

Growth & Financials

Annexon, Inc. (ANNX) grew revenue by 0.0% over the past year. Growth has been modest.

Annexon, Inc. (ANNX) reported a net loss of $207.0M for fiscal year 2024.

Dividend & Returns

Annexon, Inc. (ANNX) has a return on equity (ROE) of -50.8%. Negative ROE indicates the company is unprofitable.

Annexon, Inc. (ANNX) had negative free cash flow of $176.6M in fiscal year 2024, likely due to heavy capital investments.